ziptides semaglutide Compounded Kit Drugmakers and pharmacists battle over

Furthermore, on February 2025, Biocon Limited , an innovation-driven global biopharmaceutical business, has announced the launch of Liraglutide, a GLP-1 peptide for diabetes and obesity, in the United Kingdom

Biguanides, once responsible for more than 35% of prescriptions, have steadily lost share as patients and providers increasingly turn to GLP1s

For more information on GLP-1 Support from Whole Health Rx, visit www.vitaminshoppe.com/lp/glp1-weightloss.

doi: 10.1001/archneur.63.2.189 88 HuangY.HapponenK

But according to conservative estimates, 2 million patients have taken compounded GLP-1s, which are not approved by the U.S